Biosimilar medicines are manufactured, distributed and monitored according to the same standards as other medicines1. In line with all other medicinal products, biosimilar medicines are permanently monitored post approval, to ensure continued safety and efficacy5. Robust pharmacovigilance activities, including routine pharmacovigilance procedures and additional specific monitoring detailed in a Risk Management Plan (RMP), ensure patient … Continue reading Post marketing surveillance